Serologicals subsidiary expands distribution agreement with Novo Nordisk

By Lisa Kerner

Erie, Pa., March 16 - Celliance Corp., a wholly owned subsidiary of Serologicals Corp., said it formed an expanded four-year supply agreement with Novo Nordisk A/S, giving Celliance the worldwide exclusive right to distribute Novo Nordisk's recombinant human insulin in the cell culture market.

"The agreement that we just concluded allows us to renew our commitment to our cell culture customers for another four years," Serologicals president and chief executive officer David A. Dodd said in a company news release.

"We will continue to market this important product to our customers under our Incelligent brand."

Atlanta-based Celliance makes bioprocessing products and provides related services.

Serologicals, also based in Atlanta, develops and commercializes consumable biological products.

Novo Nordisk is a health care company based in Bagsvaerd, Denmark, that specializes in diabetes care.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.